The AIM-traded medical device group now expects FY26 revenue growth of 50% to 60%, narrowed from previous guidance of 40% to 60%, and said recent updates on Speedboat, SpydrBlade Flex and MicroBlate Fine showed broader clinical and commercial traction.
Creo said it remained focused on efficiency after the sale and outsourcing of manufacturing, expected to cut annual operating costs by more than £1.0m, while a £5.5m placing and £2.0m convertible loan note subscription from the Development Bank of Wales would support inventory, customer roll-out and expansion.
At 1334 BST, shares in Creo Medical Group were up 8.89% at 14.7p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate